Literature DB >> 11985532

Down-regulated donor-specific T-cell reactivity during successful tapering of immunosuppression after kidney transplantation.

N M van Besouw1, B J van der Mast, P de Kuiper, P J H Smak regoor, Lenard M B Vaessen, J N M Ijzermans, T van Gelder, W Weimar.   

Abstract

Stable cadaveric renal transplant patients were routinely converted from cyclosporin A (CsA) to either azathioprine (AZA) or mycophenolate mofetil (MMF) 1 year after transplantation to reduce the side effects of long-term immunosuppressive therapy. Thereafter, the AZA and MMF dose was gradually tapered to 50% at 2 years after transplantation. We questioned whether a reduction of immunosuppressive treatment results in a rise of donor-specific T-cell reactivity. Before transplantation (no immunosuppression), 1 year (high dose immunosuppression) and 2 years (low dose immunosuppression) after transplantation, the T-cell reactivity of peripheral blood mononuclear cells (PBMC) against donor and third-party spleen cells was tested in mixed lymphocyte cultures (MLC) and against tetanus toxoid (TET) to test the general immune response. We also measured the frequency of donor and third-party reactive helper (HTLpf) and cytotoxic (CTLpf) T-lymphocyte precursors in a limiting dilution assay. Donor-specific responses, calculated by relative responses (RR = donor/third-party reactivity), were determined. Comparing responses after transplantation during high dose immunosuppression with responses before transplantation (no immmunosuppression), the donor-specific MLC-RR (P = 0.04), HTLp-RR (P = 0.04) and CTLp-RR (P = 0.09) decreased, while the TET-reactivity did not change. Comparing the responses during low dose with high dose immunosuppression, no donor- specific differences were found in the MLC-RR, HTLp-RR and CTLp-RR, although TET-reactivity increased considerably (P = 0.0005). We observed a reduction in donor-specific T-cell reactivity in stable patients after renal transplantation during in vivo high dose immunosuppression. Tapering of the immunosuppressive load had no rebound effect on the donor-specific reactivity, while it allowed recovery of the response to nominal antigens.

Entities:  

Mesh:

Year:  2002        PMID: 11985532      PMCID: PMC1906400          DOI: 10.1046/j.1365-2249.2002.01810.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  Induction of donor-specific tolerance or sensitization as measured by sequential MLC reactivity up to 24 months after renal transplantation.

Authors:  D Kahn; E du Toit; J E Jacobson; P Creemers
Journal:  Transpl Int       Date:  1994       Impact factor: 3.782

2.  Withdrawal of mycophenolate mofetil in stable renal transplant recipients.

Authors:  B Kaplan; H U Meier-Kriesche; M Vaghela; G Friedman; S Mulgaonkar; M Jacobs
Journal:  Transplantation       Date:  2000-04-27       Impact factor: 4.939

3.  Hypertension in renal transplant recipients on cyclosporin A and corticosteroids and azathioprine.

Authors:  D V Hamilton; D J Carmichael; D B Evans; R Y Calne
Journal:  Transplant Proc       Date:  1982-09       Impact factor: 1.066

4.  Decreased donor-specific cytotoxic T cell precursor frequencies one year after clinical lung transplantation do not reflect transplantation tolerance: a comparison of lung transplant recipients with or without bronchiolitis obliterans syndrome.

Authors:  A de Haan; I van der Gun; B G Hepkema; W J de Boer; W van der Bij; L F de Leij; J Prop
Journal:  Transplantation       Date:  2000-04-15       Impact factor: 4.939

5.  Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced.

Authors:  N M van Besouw; B J van der Mast; P de Kuiper; P J Smak Gregoor; L M Vaessen; J N IJzermans; T van Gelder; W Weimar
Journal:  Transplantation       Date:  2000-07-15       Impact factor: 4.939

6.  Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction.

Authors:  P J Smak Gregoor; T van Gelder; N M van Besouw; B J van der Mast; J N IJzermans; W Weimar
Journal:  Transplantation       Date:  2000-07-15       Impact factor: 4.939

Review 7.  Cyclosporine nephrotoxicity: pathogenesis, prophylaxis, therapy, and prognosis.

Authors:  B D Kahan
Journal:  Am J Kidney Dis       Date:  1986-11       Impact factor: 8.860

8.  Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial.

Authors: 
Journal:  Lancet       Date:  1983-10-29       Impact factor: 79.321

9.  A randomized clinical trial of cyclosporine in cadaveric renal transplantation.

Authors: 
Journal:  N Engl J Med       Date:  1983-10-06       Impact factor: 91.245

10.  Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients.

Authors:  T E Starzl; G B Klintmalm; R Weil; K A Porter; S Iwatsuki; G P Schroter; C Fernandez-Bueno; N MacHugh
Journal:  Surg Gynecol Obstet       Date:  1981-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.